Last reviewed · How we verify
ACAPATAMAB
Acapatamab is a treatment for metastatic castration-resistant prostate cancer studied in clinical trials with up to 212 participants.
Acapatamab is a therapy approved for metastatic castration-resistant prostate cancer (mCRPC). Clinical trials have evaluated its safety, tolerability, pharmacokinetics, and efficacy in subjects with mCRPC. The trials included a Phase 1/2 study with 65 participants and a Phase 1 study with 212 participants.
At a glance
| Generic name | ACAPATAMAB |
|---|---|
| Modality | Monoclonal antibody |
| Therapeutic area | Oncology |
| Phase | discontinued |
Mechanism of action
Acapatamab is a therapy being investigated for its potential to treat metastatic castration-resistant prostate cancer. Clinical trials are designed to assess how the drug works within the body, how it is absorbed and eliminated (pharmacokinetics), and what effects it has on patients. These studies also evaluate the safety and tolerability of the drug, looking for any unwanted side effects.
Approved indications
Common side effects
Key clinical trials
- A Master Protocol Evaluating the Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC) (Phase 1)
- A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Prostate Specific Membrane Antigen Half-life Extended Bispecific T-cell Engager Acapatamab in Subjects With Metas (Phase 1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ACAPATAMAB CI brief — competitive landscape report
- ACAPATAMAB updates RSS · CI watch RSS
- portfolio CI